Viela Bio, Inc.
Viela Bio, Inc., a prominent player in the biotechnology industry, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a leader in developing innovative therapies for autoimmune and inflammatory diseases. With a strong focus on monoclonal antibodies, Viela Bio's core products, including its flagship treatment, are designed to address unmet medical needs, setting them apart in a competitive market. The company operates primarily in North America and has made significant strides in clinical development, achieving key milestones that underscore its commitment to advancing patient care. Recognised for its scientific expertise and dedication to innovation, Viela Bio continues to enhance its market position, contributing to the evolving landscape of biopharmaceuticals.
DitchCarbon Score
How does Viela Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viela Bio, Inc.'s score of 49 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Viela Bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for reporting. The company is a current subsidiary of Amgen Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family relationship with Amgen Inc., Viela Bio may align with the sustainability initiatives and targets set by Amgen. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the level of Amgen Inc. While specific reduction targets or achievements for Viela Bio are not disclosed, the overarching commitments from Amgen Inc. may influence its climate strategy. Amgen has been actively working towards reducing its carbon footprint and enhancing sustainability practices across its operations. In summary, while direct emissions data for Viela Bio, Inc. is not available, the company is likely to be guided by the climate commitments and initiatives of its parent company, Amgen Inc., as part of its broader corporate sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viela Bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
